Skip to content

Alnylam buy, $73 target reiterated by BMO

April 18, 2017

BMO Capital reiterates Outperform rating and $73 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) following the release of positive results for Emicizumab, a competing hemophilia drug.

Analyst Do Kim notes that despite the positive results from Emicizumab, enthusiasm for Fitusiran has not diminished, as confidence remains in Fitusiran ability to excel in hemophilia with inhibitors market, offering than Fitusiran’s once a month dosing is superior to Emicizumab once a week dosing.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: